FIG. 3.

Combination of a nucleoside inhibitor with either VX-950 or HCV-796 results in additive inhibitory activity against the replicon. Huh7 cells that stably maintain a GT 1b subgenomic replicon were treated with various concentrations of a nucleoside inhibitor, either R1479 (A and B) or PSI-6130 (C and D), and either HCV-796 (A and C) or VX-950 (B and D). After 72 h, the inhibitory activity of the compounds was determined by measuring the reduction in luciferase activity. The activity of the inhibitors in combination was determined from at least three experiments and is reported as percent synergy.